1. Blombery, P.A., Wall, M., and Seymour, J.F., The molecular pathogenesis of B-cell non-Hodgkin lymphoma, Eur. J. Haematol., 2015, vol. 95, no. 4, pp. 280–293.
2. Van Valkenburg, M.E., Pruitt, G.I., Brill, I.K., et al., Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features, Cancer Causes Control, 2016, no. 27, pp. 81–91.
3. Voropaeva, E.N., Pospelova, T.I., Voevoda, M.I., et al., Association of DNA repair gene XRCC1 polymorphism Arg399Gln with high-grade non-Hodgkin’s lymphoma risk, Gematol. Transfuziol., 2013, vol. 58, no. 1, pp. 10–14.
4. Berezina, O.V., Vainer, A.S., Voropaeva, E.N., et al., Influence of single-nucleotide replacements in genes of folate cycle on risk of aggressive non-Hodgkin’s lymphoma development, Sib. Med. Obozr., 2011, vol. 3, no. 69, pp. 22–26.
5. Fan, C., Wei, J., Yuan, C., et al., The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to non-Hodgkin lymphoma risk, PLoS One, 2014, vol. 9, no. 9. e107047